Filter posts

What's New at ImmunoVaccine Technologies

An interview with Dr. Randal Chase, President & CEO of ImmunoVaccine Technologies: Can you describe …

A Word with Calistoga Pharmaceuticals' CEO

An interview with Dr. Carol Gallagher, Pharm.D., CEO of Calistoga Pharmaceuticals: Can you describe the …

XOMA to Repay Goldman Sachs Loan in Full

XOMA Ltd. (Nasdaq:XOMA) announced a plan to repay its loan with Goldman Sachs Specialty Holdings, …

Newron Announces Positive Results for Ralfinamide

Newron Pharmaceuticals SpA, announced positive preclinical study results showing that ralfinamide has statistically significant benefits …

Flu Study Finds Only One H1N1 Vaccine Shot Needed

Early results from clinical trials show that the majority of healthy adults may only need …

Team at BrainCells using brain cells

An interview with James A. Schoeneck, Chief Executive Officer, BrainCells, Inc.: Can you describe the …

Anadys Pharmaceuticals Begins Phase II Study Dosing of ANA598

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II …

XOMA Collaboration with Arana Therapeutics

XOMA Ltd. (Nasdaq:XOMA) and Arana Therapeutics Limited, a wholly-owned subsidiary of Cephalon, Inc. (Nasdaq:CEPH) will …

PTC Therapeutics Announces Phase III Trial of Ataluren

PTC Therapeutics, Inc. (PTC) initiated a Phase III trial of ataluren, an investigational protein restoration …

The latest from Trubion Pharmaceuticals

An interview with Dr. Peter A. Thompson, MD, FACP, President, CEO, & Chairman of the …